製品名:5-(Methylsulfonyl)nicotinic acid

IUPAC Name:5-methanesulfonylpyridine-3-carboxylic acid

CAS番号:893723-59-6
分子式:C7H7NO4S
純度:97%
カタログ番号:CM178877
分子量:201.2

包装単位 有効在庫 価格(USD) 数量
CM178877-250mg in stock ƥƛũ
CM178877-1g 1-2 Weeks ƿƥŵ

研究開発用専用.

問い合わせフォーム

   refresh    

製品詳細

CAS番号:893723-59-6
分子式:C7H7NO4S
融点:-
SMILESコード:O=C(O)C1=CN=CC(S(=O)(C)=O)=C1
密度:
カタログ番号:CM178877
分子量:201.2
沸点:503.1±50.0°C at 760 mmHg
MDL番号:MFCD06254799
保管方法:Store at 2-8°C.

Category Infos

Pyridines
Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.
Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu
Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer
Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

Column Infos

Nelutroctiv
The Journal of Medicinal Chemistry recently publishes an article titled, “Discovery of Nelutroctiv (CK-136), a Selective Cardiac Troponin Activator for the Treatment of Cardiovascular Diseases Associated with Reduced Cardiac Contractility”. Heart failure (HF) is a lifelong clinical syndrome and remains a major societal concern. Cardiac myosin activators constitute a new class of inotropes and are found to be a viable therapeutic approach for increasing myocardial contractility.
CK-136 is a small molecule cardiac troponin activator that is discovered under a previous joint research program between Cytokinetics and Amgen. It acts on the sarcomere and is designed to improve myocardial contractility by sensitizing cardiac troponin to calcium, increasing actin-myosin cross bridge formation during each cardiac cycle. CK-136 is developed as a potential treatment for heart failure (HF) with reduced ejection fraction (HFrEF) and other types of heart failure, and currently under phase 1 clinical investigation.

Related Products